Clinical Trial Update: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 clinical trial evaluating the combination of lenalidomide and ibrutinib in patients with relapsed or refractory B-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Revlimid (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING